- Report
- March 2024
- 132 Pages
Global
From €865EUR$950USD£734GBP
- Report
- December 2024
- 348 Pages
Global
From €1692EUR$1,859USD£1,437GBP
€2416EUR$2,655USD£2,052GBP
- Report
- December 2024
- 90 Pages
United States
From €1387EUR$1,524USD£1,178GBP
€1981EUR$2,177USD£1,683GBP
- Report
- November 2024
- 110 Pages
North America
From €1556EUR$1,710USD£1,322GBP
€2224EUR$2,443USD£1,889GBP
- Report
- November 2024
- 90 Pages
Australia
From €1184EUR$1,301USD£1,006GBP
€1692EUR$1,859USD£1,437GBP
- Report
- November 2024
- 150 Pages
United Kingdom
From €1269EUR$1,394USD£1,077GBP
€1812EUR$1,991USD£1,539GBP
- Report
- November 2024
- 130 Pages
Asia Pacific
From €1184EUR$1,301USD£1,006GBP
€1692EUR$1,859USD£1,437GBP
- Report
- November 2024
- 150 Pages
Europe
From €1438EUR$1,580USD£1,221GBP
€2054EUR$2,257USD£1,745GBP
- Report
- April 2024
- 350 Pages
Global
From €2447EUR$2,688USD£2,078GBP
€3495EUR$3,840USD£2,969GBP
- Report
- November 2022
- 310 Pages
Global
From €2447EUR$2,688USD£2,078GBP
€3495EUR$3,840USD£2,969GBP

Live attenuated vaccines are a type of vaccine that use a weakened form of a virus or bacteria to stimulate an immune response. These vaccines are designed to replicate the natural infection process, allowing the body to develop immunity without the risk of serious illness. Live attenuated vaccines are typically administered orally or nasally, and are often used to protect against diseases such as measles, mumps, rubella, and rotavirus.
Live attenuated vaccines are generally considered to be safe and effective, and are often used in combination with other vaccines to provide broader protection. They are also cost-effective, as they require fewer doses than other types of vaccines.
Notable companies in the live attenuated vaccine market include Merck & Co., GlaxoSmithKline, Sanofi Pasteur, Pfizer, and Novartis. Show Less Read more